ProCE Banner Activity

CLIMB THAL-111/SCD-121: Phase I/II Studies of CTX001 for Transfusion-Dependent β-Thalassemia and Sickle Cell Disease

Slideset Download
Conference Coverage
Among the first 10 study participants with ≥ 3 months of follow-up, CTX001 infusion achieved cessation of pRBC transfusions for TDT patients, and eliminated veno-occlusive events for severe SCD patients.

Released: December 16, 2020

Expiration: December 15, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology